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AbstrAct
We identified a synthetic lethality between PLK1 silencing and the expression of an 
oncogenic Epidermal Growth Factor Receptor, EGFRvIII. PLK1 promoted homologous 
recombination (HR), mitigating EGFRvIII induced oncogenic stress resulting from DNA 
damage accumulation. Accordingly, PLK1 inhibition enhanced the cytotoxic effects 
of the DNA damaging agent, temozolomide (TMZ). This effect was significantly more 
pronounced in an Ink4a/Arf(-/-) EGFRvIII glioblastoma model relative to an Ink4a/
Arf(-/-) PDGF-β model. The tumoricidal and TMZ-sensitizing effects of BI2536 were 
uniformly observed across Ink4a/Arf(-/-) EGFRvIII glioblastoma clones that acquired 
independent resistance mechanisms to EGFR inhibitors, suggesting these resistant 
clones retain oncogenic stress that required PLK1 compensation. Although BI2536 
significantly augmented the anti-neoplastic effect of EGFR inhibitors in the Ink4a/
Arf(-/-) EGFRvIII model, durable response was not achieved until TMZ was added. 
Our results suggest that optimal therapeutic effect against glioblastomas requires a 
“multi-orthogonal” combination tailored to the molecular physiology associated with 
the target cancer genome.
IntroductIon
It has long been observed that expression of potent 
oncogenes frequently induces cell cycle arrest, death, 
or senescence [1]. From these observations emerged 
the notion that oncogenic activation is accompanied by 
“oncogenic stress” that is prohibitive to cell survival or 
proliferation [2]. In this paradigm, cellular adaptation to 
these stresses through compensatory events is a requisite 
for neoplastic transformation and tumor viability [3, 
4]. Implicit within this framework is the concept that 
oncogenic cell states are sensitive to inhibition of these 
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compensatory mechanisms [5]. These forms of synthetic 
lethality have been born out in a number of studies 
demonstrating selective ablation of cells expressing 
potent oncogenes through inhibition of compensatory 
mechanisms [6, 7]. Notably, many oncogenic drivers 
induce DNA accumulation as a form of oncogenic stress 
[8, 9], requiring up-regulation of DNA repair or altered 
DNA damage response (DDR) for cell viability [10, 11]. 
Importantly, up-regulation of DDR has not been 
reported as resistance mechanisms for inhibitors targeting 
oncogenic proteins [12, 13]. Similarly, cancer cells that 
emerged after treatment with DNA damaging agents have 
not exhibited significant alteration in oncogenic signaling 
[14]. These observations suggest the possibility of 
imposing parallel and “orthogonal” [4] selections against 
the oncogenic state by simultaneous inhibition of DDR, 
thereby exacerbating the deleterious effects of oncogenic 
stress, and inhibition of the pertinent oncoprotein. 
Cancer cells subjected to such combination will need to 
independently evolve resistance mechanisms to restore 
oncogenic signaling as well as adaptive mechanisms to 
oncogenic stress. We tested this hypothesis in the context 
of an oncogenic form of Epidermal Growth Factor 
Receptor (EGFR), termed EGFRvIII [15]. 
EGFRvIII is a recurrent oncogenic variant found in 
25-64% of glioblastomas [16-18], the most common form 
of primary brain cancer [19, 20]. This variant harbors 
a deletion that spans exons 2-7 of EGFR, a region that 
encodes a significant portion of the EGFR extracellular 
ligand-binding domain [17]. EGFRvIII is essential for 
glioblastoma initiation as well as proliferation [15]. In 
clinical specimens, EGFRvIII expression is typically 
detected in only a small portion of glioblastoma cells [3, 
17]. However, clinical efficacy has been reported with 
selective ablation of this cell sub-population [21, 22], 
suggesting these EGFRvIII expressing glioblastoma cells 
exert potent effect on the biology of the overall tumor 
mass [23]. 
Our previous study demonstrated that EGFRvIII 
expression in glioblastomas induced oncogenic stress 
in the form of excessive DNA damage accumulation 
[11]. Here, we report that polo-like kinase 1 (PLK1) 
compensates for this stress through modulation of 
homologous recombination (HR). The tumoricidal 
and TMZ-sensitizing effects of the PLK1 inhibitor, 
BI2536, depends on the intrinsic physiology of the 
glioblastoma and correlated with the endogenous levels 
of DNA damage. Supporting our hypothesis, BI2536 
augmented the ablative effects of Gefitinib, an EGFR 
inhibitor. However, durable response in a Ink4a/Arf(-/-) 
EGFRvIII model was not observed until temozolomide 
(TMZ), a DNA alkylating agent and the standard-of-care 
chemotherapy for glioblastoma, was added to the regimen. 
We termed this strategy “multi-orthogonal” because each 
component of the regimen acts in an orthogonal manner 
relative to others. 
results
synthetic lethality between eGFrvIII expression 
and PlK1 inhibition
To identify DDR genes required for compensating 
EGFRvIII-associated oncogenic stress, we screened 714 
siRNAs directed against 357 DDR genes for preferential 
toxicity to EGFRvIII over-expressing U87MG (U87MG 
EGFRvIII) cells relative to its parental cells (Figure 1A). 
Top candidates were highly enriched for DDR genes 
involved in homologous recombination (HR) (Figure 1B, 
shown in red). The top scoring hit, PLK1, was selected for 
subsequent validation because of the availability of clinical 
grade PLK1 inhibitors [11]. To exclude the possibility 
of off-target effects, two additional PLK1 siRNAs were 
tested, and both exerted preferential toxicity to the 
U87MG EGFRvIII cells (0% viable) relative to U87MG 
parental cells (50-60% viable, Figure 1C). Moreover, 
BI2536, a PLK1 inhibitor, completely ablated Ink4a/Arf(-
/-) EGFRvIII cells while minimally affecting the parental 
Ink4a/Arf(-/-) astrocytes at a 12 nM concentration (Figure 
1D).
Hyper-activation of PlK1 in eGFrvIII 
expressing glioblastomas
The synthetic lethal interaction suggests that 
EGFRvIII expressing glioblastomas harbored heightened 
requirement of PLK1 activity. Consistent with this 
hypothesis, we found increased levels of an active form of 
PLK1 (pT210 PLK1) in U87MG EGFRvIII cells relative 
to U87MG cells. The increase in pT210 PLK1 was found 
in both synchronous and asynchronous cell populations 
(Figure 1E), indicating that the difference was independent 
of cell cycle progression. Similar results were observed 
in U178MG human glioblastoma cells conditionally 
expressing EGFRvIII (U178MG tet-EGFRvIII) (Figure 
1F). These results suggest that EGFRvIII expressing 
human glioblastomas harbored higher levels of active 
PLK1.
PlK1 inhibition enhanced accumulation of 
mitotic dnA damages
A previous genome-wide siRNA screen revealed 
that PLK1 silencing led to a significant induction in 
γH2AX formation, suggesting PLK1 suppressed DNA 
damage accumulation [24]. In the context of our previous 
finding that EGFRvIII expression is associated with an 
elevated level of DNA damage [11], we hypothesized that 
PLK1 prevented the lethal accumulation of DNA damage 
in EGFRvIII expressing glioblastomas. Supporting this 
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Figure 1: silencing or inhibition of PlK1 is preferentially toxic to u87MG eGFrvIII cells. A. Schematic depiction of 
siRNA library screen. b. The top siRNA targets that, when silenced, were preferentially toxic to the U87MG EGFRvIII cells relative 
to the U87MG parental cells. Red: DDR genes involved in HR. The “% increase in cytotoxicity” was calculated based on the mean 
of two independent experiments. c. (left) Immunoblot of PLK1 following knockdown with two independent siRNAs, siPLK1-1 (si-1) 
and siPLK1-2 (si-2). Negative control siRNA is indicated as n. Whole cell lysates were collected 48 h after siRNA transfection. (right) 
Clonogenic survival following PLK1 siRNA transfection in U87MG parental and U87MG EGFRvIII cells. **, p = 0.0092 and 0.0019 
respectively. d. Effect of BI2536 on murine Ink4a/Arf(-/-) EGFRvIII cells and parental Ink4a/Arf(-/-) astrocytes. Clonogenic survival was 
determined after 14 days treatment. **, p = 0.0027 and 0.0036 respectively. e. (left upper) Schematic depiction of cell synchronization 
by double thymidine blocking (DTB). (left lower) Cell cycle distribution of U87MG parental and U87MG EGFRvIII cells after DTB. 
(middle) Representative immunoblots of whole cell lysates derived from synchronized and asynchronous U87MG parental (p) and U87MG 
EGFRvIII (vIII) cells. (right) Quantitative densitometric assessment of pT210 PLK1 was normalized to the total PLK1 after correcting 
for protein loading using β-actin level respectively. asyn, asynchronized cells; R-8 h, synchronized cells released from DTB for 8 h. *, p = 
0.044; **, p = 0.0014. F. (left upper) Cell cycle distribution of U178MG tet-EGFRvIII cells with or without doxycycline (Dox) treatment 
at 1 µg/mL for 96 h; (left lower) Representative immunoblots of U178MG tet-EGFRvIII cell lysates with or without Dox treatment; (right) 
Quantitative densitometric assessment of pT210 PLK1 as above described. **, p = 0.0058. The densitometric results represent the average 
of three experiments, shown as mean±SD. 
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hypothesis, PLK1 inhibition by BI2536 induced a ~ 3-fold 
increase in γH2AX accumulation; this increase was further 
magnified by EGFRvIII expression (by an additional 2-3 
fold, Figure 2A). Similar results were observed using the 
Comet assay (Figure 2B). 
Given PLK1’s role in mediating cellular adaptation 
[25], we explored the possibility that PLK1 inhibition 
may alter the cell-cycle distribution of DNA double-
strand breaks (DSBs). U87MG parental or EGFRvIII cells 
were co-stained with the antibodies against γH2AX and 
histone H3 phosphorylated at serine 10 (pH3) in order to 
discriminate DSBs present during mitosis (pH3+) versus 
interphase (pH3-) respectively. EGFRvIII expressing cells 
exhibited increased γH2AX foci throughout the cell cycle 
(Figure 2C). BI2536 treatment of U87MG EGFRvIII 
cells increased the proportion of pH3+ cells with γH2AX 
foci, without significantly altering the proportion of pH3- 
cells with γH2AX foci (Figure 2C). Similar results were 
observed with flow cytometric analysis of cells co-stained 
with antibodies against γH2AX and pH3 (Supplemental 
Figure 1). These results suggest that PLK1 inhibition 
predominantly enhanced DSBs accumulation during the 
mitosis of the cell cycle. 
eGFrvIII expression is associated with aberrant 
mitotic progression
We next tested whether the accumulation of mitotic 
DNA damage in U87MG EGFRvIII cells was associated 
with aberrant mitotic progression. Time-lapse imaging of 
H2B-GFP labeled cells indicated that, on average, U87MG 
EGFRvIII cells required 108.4 minutes to complete 
mitosis, compared to the 61.5 minutes required for 
U87MG parental cells. Moreover, 33.3% of the U87MG 
EGFRvIII cells underwent aberrant mitosis (compared 
to 3.8% of U87MG parental cells, Figure 2D). Further 
analysis revealed that U87MG EGFRvIII cells were more 
prone to form multipolar or monopolar mitotic spindles 
relative to the U87MG parental cells. 25% of the scored 
mitosis in the U87MG EGFRvIII population were either 
multipolar (17%) or monopolar (8%) while none of the 
mitosis scored in the U87MG parental cells exhibited these 
phenotypes (Figure 2E). Treatment with TMZ resulted in a 
significant increase in mitotic death for U87MG EGFRvIII 
cells, but not for U87MG cells — despite a near 10-fold 
increase in the frequency of aberrant mitosis in these cells 
(Supplemental Figure 2). These observations suggest that 
DNA damage accumulation is i) associated with aberrant 
mitotic progression, and ii) associated with mitotic death 
in the context of EGFRvIII expression. 
bI2536 treatment inhibited PlK1 mediated 
phosphorylation of rad51 ser14, and 
compromised homologous recombination
PLK1 has been shown to phosphorylate Rad51 at 
serine residue 14 (pS14 Rad51) in HeLa and 293T cells 
to facilitate HR [26]. Given that PLK1 inhibition resulted 
in an increased level of DNA damage in EGFRvIII 
expressing glioblastoma cells, we next tested whether 
the PLK1-mediated Rad51 phosphorylation played a 
significant role in glioblastomas. The level of pS14 Rad51 
was approximately 3-4-fold higher in U87MG EGFRvIII 
cells relative to U87MG parental cells in synchronized 
cell populations (Figure 3A). This level was suppressed 
by treatment with BI2536 (Figure 3B). BI2536 treatment 
also reduced the efficiency of HR by approximately 50% 
in the established DR-GFP assay [27] in both U87MG 
glioblastoma and U2OS osteosarcoma cells (Figure 
3C). Taken together, these results suggest that PLK1 
counteracts excessive DNA damage accumulation by 
promoting HR in EGFRvIII expressing glioblastoma cells. 
Consistent with this interpretation, siRNAs against Rad51 
and BRCA2, two genes essential for HR [26], caused 
significantly higher toxicity in U87MG EGFRvIII cells 
relative to U87MG cells. Silencing Rad51 or BRCA2 did 
not further enhance the cytotoxic effect of BI2536 (Figure 
3D and Supplemental Figure 3). 
PlK1 inhibition augments the tumoricidal effect 
of tMZ in vitro and in vivo
Since inhibition of DDR and induction of DNA 
damage often result in synergistic tumor ablation [28], 
our results suggest that PLK1 inhibition would enhance 
the tumoricidal effect of TMZ, the DNA damaging 
chemotherapeutic agent routinely used in glioblastoma 
treatment. In clonogenic assays, the combination of 
BI2536 and TMZ treatment led to synergistic ablation 
of U87MG EGFRvIII cells. Exposure to 100 µM of 
TMZ and 12 nM of BI2536 led to approximately 50% 
and 30% reduction in viability, respectively. Combined 
treatment led to complete ablation of U87MG EGFRvIII 
cells (Figure 4A). Similar results were obtained using the 
murine Ink4a/Arf(-/-) and Ink4a/Arf(-/-) EGFRvIII cells 
(Figure 4B).
To confirm the validity of these results in vivo, we 
tested the combination therapy using U87MG parental 
and U87MG EGFRvIII in a murine subcutaneous model. 
Treatment was initiated 7 days after implantation, with 
tumor sizes < 100 mm3. Under these conditions, the 
U87MG parental xenografts were exquisitely sensitive 
to TMZ treatment, with complete regression after TMZ 
treatment (Figure 4C, left). For the U87MG EGFRvIII 
cells, the volumetric ratios of TMZ-treated and BI2536-
treated tumors relative to vehicle treated tumors 
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Figure 2: bI2536 treatment leads to increased dnA damage accumulation in u87MG eGFrvIII cells. A. (left) 
Representative immunoblots of U87MG and U87MG EGFRvIII cells treated with vehicle or 25 nM BI2536 for 24 h. (right) Quantitative 
densitometric assessment of γH2AX level normalized to β-actin. **, p = 4.92×10-5 and 0.0012 respectively. b. (left) Representative comet 
staining images in U87MG EGFRvIII cells and U87MG parental cells after BI2536 treatment (25 nM for 24 h). (right) Quantitative 
assessment of comet tail moment. **, p = 0.01; *, p = 0.037. c. U87MG EGFRvIII cells and U87MG parental cells were stained for γH2AX 
and pH3 after 24 h treatment with 5 nM BI2536 or control. (left) Representative immunofluorescence staining. (right) Quantitation of 
γH2AX foci in pH3+ (M) and pH3- (I) cells. Approximately 100 cells were scored. **, p = 0.0063; *, p = 0.035 and 0.036 for vehicle control 
respect to BI2536 treated samples correspondingly. d. (left) Representative images of aberrant mitotic progression in U87MG EGFRvIII 
H2B-GFP cells. Time elapsed was indicated in the right lower corner (h:min). Arrow marks a lagging chromosome (see arrow at hour 
2:00). (right) Frequencies of aberrant mitotic events in U87MG parental and U87MG EGFRvIII cells. Length of mitosis was scored from 
the onset of prophase to the onset of anaphase. Approximately 100 cells were scored, respectively. e. Aberrant multipolar and monopolar 
mitotic spindles in the U87MG EGFRvIII cells. (left) U87MG parental and U87MG EGFRvIII cells were stained for α-tubulin and the 
centrosome protein Cep192. (right) Quantification of bipolar, multipolar, and monopolar mitotic figures in U87MG parental and U87MG 
EGFRvIII cells.
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(Treatment/Control or T/C ratio, at day 25) were 64% and 
79.1%, respectively. In comparison, tumors treated with 
both TMZ and BI2536 showed a T/C ratio of 1.9% (Figure 
4C, right).
The effects of BI2536 and TMZ were further 
characterized in an orthotopic model where glioblastoma 
derived from an Ink4a/Arf(-/-) EGFRvIII model [29] was 
intracranially implanted into athymic nude mice. In this 
model, TMZ and BI2536 treatment prolonged the median 
survival of intracranial Ink4a/Arf(-/-) EGFRvIII tumor-
bearing mice from 25 days (vehicle treated) to 32.5 days 
and 29.5 days, respectively. The combination further 
improved the median survival to 41 days (Figure 4D). 
Collectively, our results suggest that BI2536 augmented 
the tumoricidal activity of TMZ.
Figure 3: bI2536 inhibits phosphorylation of rad51 s14 and compromises Hr in glioblastoma cells. A. (left) Representative 
immunoblots of U87MG parental (p) and U87MG EGFRvIII (vIII) cells for pS14 Rad51, Rad51, and Ku86. asyn, asynchronized cells; R-8 
h, synchronized cells released from DTB for 8 h. (right) pS14Rad51 was normalized to the total Rad51 after correcting for protein loading 
using Ku86 level. **, p = 0.0026; *, p = 0.045. b. (left) Representative immunoblot of whole U87MG EGFRvIII cell lysate following 
24 h treatment with control or 10 nM BI2536. (right) Quantitative densitometric assessment as above described. **, p = 0.0018.c. (left) 
Schematic summary of the DR-GFP assay. (right) Percentage of GFP-positive cells detected by FACS using U2OS DR-GFP and U87MG 
DR-GFP cells, separately. GFP-positive cells were scored after treatment with BI2536 (25 nM) or control for 24 h. **, p = 0.00056 and 
0.00057 respectively. d. The effects of RAD51 and BRCA2 knockdown in U87MG parental and U87MG EGFRvIII cells. Cells were 
transfected with the various siRNAs for 24 h and re-plated overnight. BI2536 (25 nM) or control were then added. Clonogenic survivals 
were scored after additional 14 days. All results were shown as mean±SD. 
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context dependency of PlK1 inhibition
EGFRvIII and PDGF-β are driver oncogenes for 
the classical and proneural subtypes of glioblastoma, 
respectively [20]. Characterization of murine 
glioblastomas formed in the Ink4a/Arf(-/-) EGFRvIII [30] 
and Gtv-a Ink4a/Arf(-/-) PDGF-β model [31] revealed 
significantly higher levels of DNA damage accumulation 
in the former, as evidenced by the levels of γH2AX 
(Figure 5A). If the therapeutic effect of PLK1 inhibition 
is related to the endogenous level of DNA damage, we 
would predict that BI2536 would be less effective in the 
Ink4a/Arf(-/-) PDGF-β model relative to the Ink4a/Arf(-/-
) EGFRvIII model. To test this hypothesis, glioblastoma 
cells derived from these models were implanted into 
the flank of athymic nude mice. If the mice were treated 
while the tumor burden was < 100 mm3, no significant 
differences in response to BI2536 were noted (Figure 
4C versus Supplemental Figure 4). However, when the 
tumors were allowed to reach the size > 500 mm3 before 
treatment, notable difference in response to BI2536 were 
found between the two models, as shown in Figure 5B. 
BI2536 induced tumor response (as measured by tumor 
shrinkage and dormancy) for a period of 15 days in the 
Ink4a/Arf(-/-) PDGF-β model, after which tumors rapidly 
increased in size. In the Ink4a/Arf(-/-) EGFRvIII model, 
BI2536 induced tumor response for a period of 30 days 
(p < 0.05). In contrast, the anti-neoplastic effects of TMZ 
treatment were comparable in both models. These results 
suggest that the therapeutic efficacy of PLK1 inhibition 
is dependent on the glioblastoma genetic context and 
correlates with the endogenous levels of DNA damage. 
TMZ is a more non-selective tumor ablative agent.
correlation between eGFrvIII status, PlK1 
expression, and dnA damage accumulation in 
clinical glioblastoma specimens
Our results indicate that EGFRvIII expression 
is associated with increased PLK1 expression in 
glioblastoma cells (Figure 1E, 1F). We investigated 
further whether this association was also observed in 
clinical samples. Since PLK1 is expressed in a cell-cycle 
dependent manner, it is critical to control for cell-cycle 
profiles in this analysis. We utilized a previously published 
method and normalized PLK1 expression level to the 
Figure 4: bI2536 augments the tumoricidal effect of tMZ in vitro and in vivo. A. U87MG EGFRvIII cells were treated with 
TMZ (100 μM) for 24 h followed by the addition of BI2536 at 12 nM. Clonogenic survival was measured after 14 days. b. Murine Ink4a/
Arf(-/-) astrocytes and derived EGFRvIII cells were treated with TMZ (50 μM, 24h) followed by BI2536 at 5 nM. Clonogenic survivals 
were assessed as above described. *, p = 0.015; **, p = 0.0001. c. Growth curve of subcutaneous U87MG parental (left) and U87MG 
EGFRvIII (right) xenografts in nude mice. The xenograft harboring mice were treated with control, TMZ (for 3 days starting treatment at 
Day 7 after tumor implantation), BI2536 (starting at Day 13), or a combination of TMZ and BI2536 (T+B) (TMZ starting at Day 7 and 
BI2536 starting at Day 13). d. (left) Survival curve of murine Ink4a/Arf(-/-) EGFRvIII intracranial allografts bearing mice treated with 
control, TMZ (starting at Day 10), BI2536 (starting at Day 13), or combination (T+B) (starting with TMZ at Day 10, then with BI2536 at 
Day 13). (right) p values derived from survival comparisons. 5-6 mice per group for each in vivo experiment. All results were shown as 
mean±SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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expression of the two key mitotic cyclins, cyclin A and 
B [32]. A comparison using The Cancer Genome Atlas 
(TCGA) glioblastoma database revealed that EGFRvIII+ 
glioblastomas exhibited higher cyclin-normalized PLK1 
expression than the EGFRvIII- glioblastomas (Figure 6A, 
p = 0.01). In contrast, cyclin-normalized PLK1 expression 
did not correlate with PDGF-β mRNA expression (Figure 
6B, p = 0.67). 
Our data further suggest that PLK1 expression is 
associated with a cell state characterized by increased 
DNA damage accumulation. To test this association in 
clinical specimens, we identified a published mRNA 
signature that was induced upon exposure of glioblastoma 
cells to ionizing radiation [33]. We used this signature as 
a proxy for the accumulation of DNA damage. We found 
that PLK1 expression correlated with the DNA damage 
accumulation signature in TCGA dataset (Figure 6C) and 
another independent glioblastoma dataset, the Repository 
for Molecular Brain Neoplasia Data (REMBRANDT) 
(Figure 6D). Despite the difference in patient population 
and array platform, the correlation between PLK1 mRNA 
expression and DNA damage accumulation signature was 
highly significant in both datasets (p < 2.2×10-16 for both 
the TCGA and REMBRANDT dataset).
eGFr inhibitor resistant clones of glioblastoma 
remained uniformly sensitive to the PlK1 
inhibition
We determined whether glioblastoma cells with 
acquired resistance to EGFR inhibitors maintain cell states 
with oncogenic stress that require PLK1 as a compensatory 
mechanism. To test this hypothesis, we characterized the 
effect of BI2536 on a panel of 8 murine Ink4a/Arf(-/-) 
EGFRvIII clones selected for their resistance to EGFR 
Figure 5: context dependency of PlK1 inhibition. A. (left) Enhanced p-PLK1 and γH2AX in Ink4a/Arf(-/-) EGFRvIII tumors. 
3 representative tissue samples resected from murine Ink4a/Arf(-/-), Ink4a/Arf(-/-) EGFRvIII or Ink4a/Arf(-/-) PDGF-β, separately, were 
lysed and analyzed by immunoblotting using antibodies against p-PLK1, γH2AX, EGFRvIII and PDGF-β. Tubulin was loaded as loading 
control. (right) Quantitative densitometric assessment of pT210 PLK1 or γH2AX was normalized to tubulin and fold change represent the 
average of 3 samples, shown as mean±SD. *, p < 0.05; **, p < 0.01. b. BI2536 treatment exerted greater tumoricidal effect in Ink4a/Arf(-/-) 
EGFRvIII tumors compared to Ink4a/Arf(-/-) PDGF-β tumors. Ink4a/Arf(-/-) EGFRvIII or Ink4a/Arf(-/-) PDGF-β cells were implanted into 
nu/nu mice and the treatment started when the tumor size was > 500 mm3. Tumor growth was monitored twice per week and represented 
separately to represent the comparison between BI2536 or TMZ treatment.
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inhibitors. The parental Ink4a/Arf(-/-) EGFRvIII clone was 
sensitive to EGFR inhibitors. These parental cells were 
cultured in the presence of either Gefitinib (clones G1, G5, 
G12, GR-1, GR-7 and GR-11) or Erlotinib (clones E4 and 
E5) to select for acquired EGFR inhibitor resistance [34]. 
These clones utilize distinct EGFR independent-signaling 
pathways [34]. Remarkably, all resistant clones remain 
uniformly sensitive to BI2536 in vitro at concentrations 
comparable to that required to ablate the parental Ink4a/
Arf(-/-) EGFRvIII cells (Figure 7A). This effect is specific 
to EGFRvIII expressing cells, as evidenced by the lack of 
cytotoxic effect of the BI2536 (5 nM) toward the Ink4a/
Arf(-/-) astrocytes (Figure 1D).
The sensitivity of EGFR inhibitor resistant clones 
to PLK1 inhibition was further investigated using in vivo 
mice models. As shown in Figure 7B, the subcutaneous 
growth of GR-7 was modestly suppressed by TMZ 
(T/C ratio of 46.8%; Day 25) and BI2536 (T/C ratio of 
34.33%; Day 25). Combined treatment significantly 
inhibited the growth of GR-7 with T/C ratio of 19.1% 
(Day 25). The effect of PLK1 inhibition on the survival 
of G12 intracranial tumor bearing mice was determined 
in Figure 7C. TMZ and BI2536 prolonged the median 
survival of mice bearing G12 allografts to 25.5 and 28 
days, respectively, compared to 21 days in control group 
mice. Combined treatment prolonged the median survival 
to 35.5 days. These effects were near identical to those 
observed with the parental EGFR inhibitor-sensitive 
Ink4a/Arf(-/-) EGFRvIII cells (Figure 4D). In aggregate, 
these results suggest that the resistance mechanisms for 
PLK1 and EGFR inhibitors are fundamentally orthogonal 
in nature. 
Combination of Gefitinib, BI2536, and TMZ 
ablated formed tumors in a murine Ink4a/Arf(-/-) 
eGFrvIII glioblastoma model
Since our results support that Gefitinib and BI2536 
exert anti-neoplastic effects in an orthogonal manner, we 
Figure 6: clinical relevance of PlK1 level with eGFrvIII state and dnA damage accumulation signature. A. Higher 
expression of PLK1 in EGFRvIII+ glioblastoma specimens relative to EGFRvIII- specimens. p = 0.01. b. Cyclin-normalized PLK1 
expression did not correlate with PDGF-β mRNA expression. p = 0.67. c. Scatter plot showing a positive correlation between the PLK1 
expression (x-axis) and DNA damage accumulation signature score (y-axis) in TCGA clinical glioblastoma dataset. d. Similar correlation 
in REMBRANDT clinical glioblastoma dataset. Linear regression was performed to generate the best-fitting line as indicated by the black 
line. Pearson Correlation Coefficient (R2) and p-value is as indicated.
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Figure 7: bI2536 inhibits tumor growth of eGFr inhibitor-resistant murine Ink4a/Arf(-/-) eGFrvIII clones and 
sensitizes them to the dnA damaging agent tMZ. A. (upper) Clonogenic survival of murine Ink4a/Arf(-/-) EGFRvIII cells 
(parental) and established EGFR inhibitor resistant cells (erlotinib-resistant E4, E5 and gefitinib-resistant G1, G5, G12, GR-1, GR-7, 
GR-11) with BI2536 treatment. (lower) Representative colony formation images. b. (upper) Tumor growth curve of the subcutaneous 
GR-7 allografts. Nude mice bearing established GR-7 tumors in the flank were treated with control, TMZ (for 3 days starting treatment at 
Day 10 after implantation), BI2536 (starting at Day 13), or combined (T+B) (starting with TMZ at Day 10, then with BI2536 at Day 13). 
Mean tumor volume±SD are shown in 5-6 mice per group. (lower) Typical tumors isolated from each group. c. (left) Survival curve of 
intracranial G12 allografts bearing mice. The mice were treated with control, TMZ (starting at Day 10), BI2536 (starting at Day 13), or 
combined (T+B) (starting with TMZ at Day 10, then with BI2536 at Day 13) in 5-6 mice per group. (right) p values derived from survival 
comparisons. *, p < 0.05; **, p < 0.01; ***, p < 0.001. d. Tumor growth of the subcutaneous Ink4a/Arf(-/-) EGFRvIII allografts. Nude mice 
bearing established Ink4a/Arf(-/-) EGFRvIII tumors in the flank were treated as indicated in Methods. T, TMZ; B, BI2536; G, Gefitinib. 
Mean tumor volume±SD are shown in 5-6 mice per group. e. Schematic representation of “multi-orthogonal” approach. Upper panel: 
EGFRvIII expressing glioblastomas adapt to EGFR inhibition (EGFRi) by activation of alternative oncogenic signaling cascade, such as 
ones mediated by the urokinase receptor (uPAR). Other resistance mechanisms involving activation of cytoplasmic proteins, such as Src, 
have also been reported [42]. Despite the change in oncogenic signaling, the intrinsic physiological “architecture” of the transformed cells 
and the cellular dependence on DDR remain largely unaltered. Red arrow: EGFRvIII signaling. Yellow arrow: EGFR inhibition induced 
up-regulation of uPAR signaling. Bottom panel: As such, simultaneous inhibition of DDR and EGFR inhibition impose independent and 
parallel selection against glioblastoma cells. The therapeutic efficacy of the regimen is further magnified induction of additional DNA 
damage by temozolomide (TMZ), a DNA alkylating agent and the standard-of-care chemotherapy for glioblastomas.
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wished to determine whether synergy can be achieved with 
this combination. To this end, Ink4a/Arf(-/-) EGFRvIII 
cells were injected subcutaneously into the flank of 
athymic nude mice. When the average tumor volume 
exceeded 500 mm3 (see Methods), mice were randomized 
to different treatment groups (Figure 7D). Treatment 
with Gefitinib elicited tumor dormancy for 25 days, after 
which tumors became resistant and rapidly increased in 
size. While the addition of BI2536 lengthened the tumor 
response to 45 days, tumor recurrence was universal.
Since the therapeutic effect of BI2536 was enhanced 
by TMZ, we next determined whether the addition of TMZ 
to BI2536+Gefitinib further enhanced the anti-neoplastic 
effect of the regimen. The triple combination of Gefitinib, 
TMZ and BI2536 completely suppressed the tumor growth 
for 3 months. Such effect was not observed in any of the 
double combination therapies or in the Ink4a/Arf(-/-) 
PDGF-β models (Supplemental Figure 5). These results 
demonstrate the need for multi-orthogonal therapy and the 
need to tailor such therapy to the underlying molecular 
physiology of target cancer cell.
dIscussIon
With the emergence of selective inhibitors of PLK1, 
there has been growing interest in their clinical application 
to glioblastomas [35]. However, the therapeutic rationale 
remains poorly developed [36]. Moreover, no predictive 
biomarker has been identified. Through our finding of 
synthetic lethality between PLK1 and EGFRvIII and 
subsequent characterization of this genetic interaction, 
we provide the evidence that the anti-neoplastic effect 
of PLK1 inhibitors is related to the disruption of PLK1’s 
critical roles in DNA damage response. Our results 
indicate that glioblastomas harboring high levels of 
DNA damage accumulation, including those expressing 
EGFRvIII, are more likely to respond to PLK1 inhibitors 
(Figure 4E and 4F). Further, our results suggest that 
Ink4a/Arf(-/-) EGFRvIII glioblastomas that acquired 
resistance to EGFR inhibition retain oncogenic stress 
that requiring PLK1 compensation (Figure 7E, upper 
panel). As such, PLK1 and EGFR inhibitor represent 
orthogonal therapeutic agents, with enhanced tumoricidal 
activity when combined. However, the glioblastoma 
molecular circuit is sufficiently pliant that resistant clones 
eventually emerge after BI2536 + Gefitinib combination 
therapy (Figure 5D). Complete glioblastoma ablation was 
achieved only with a multi-orthogonal regimen consisting 
of BI2536, Gefitinib, and TMZ (Figure 7E, bottom panel). 
Importantly, the efficacy of such regimen is influenced 
by the genetic context of the target glioblastoma and the 
associated oncogenic stress. 
One important consideration pertaining to the 
translation of this therapeutic combination involves 
potential toxicity of the combination. Of note, the safety 
profile of each component of the combination has been 
well-documented. PLK1 inhibitors have been proved to be 
well-tolerated in phase I and II clinical trials [37] and have 
good brain blood barrier permeability [38]. Importantly, 
one PLK1 inhibitor, Volasertib (BI6727), has been 
advanced to phase III clinical trial testing as treatment 
for acute myeloid leukemia. Similarly, the clinical safety 
profiles of Gefitinib and TMZ are well-established for 
glioblastoma patients [21]. Given the observation that 
mice tolerated the combined therapy well and the safety 
profile of the individual agent, clinical translation of this 
therapeutic strategy warrants consideration. It is important 
to note that our studies were conducted in immuno-
compromised murine models. As such, exploitation 
of innate immunity against tumor [39] may afford 
opportunities to decrease the number of therapeutic agents 
required for meaningful efficacy, thereby minimizing the 
risk of treatment related toxicity.
The finding that EGFR inhibitor resistant clones 
of glioblastoma remained sensitive to PLK1 inhibition 
suggests that while the resistant glioblastoma cells 
underwent a change in oncogenic signaling, the intrinsic 
physiological “architecture” of the transformed cells 
and the cellular dependence on DDR remained largely 
unaltered. From a systems perspective, it is somewhat 
intuitive that adopting a resistance mechanism where 
an alternate oncogenic mechanism is activated to drive 
the existing cellular circuit would be less costly than 
a resistance mechanism that required a complete re-
alignment of fundamental cellular processes. As such, the 
delineation of the physiologic state of the initial tumor 
may lend therapeutic insights, particularly for tumors with 
highly pliable molecular circuits.
While it is widely appreciated that excessive DSB 
accumulation is a lethal phenomenon [25], the mechanisms 
by which DSBs trigger lethality in glioblastoma cells 
remain poorly understood [40]. The established functions 
of PLK1 [41] and the results presented here suggest 
prolonged cell cycle arrest and mitotic DNA damage 
accumulation as contributing mechanisms of DSB induced 
lethality. Supporting this thesis, the tumoricidal activities 
of PLK1 inhibition correlated with mitotic DNA damage 
accumulation (Figure 2C and Figure 1E). Moreover, 
TMZ treatment, a process that results in excessive DSB 
accumulation, significantly increased the frequency of 
aberrant mitosis and mitotic death (Figure 2E).
In summary, our study demonstrated pre-clinical 
efficacy of combining TMZ, PLK1 and EGFR inhibitors 
as treatment for EGFRvIII expressing glioblastomas. More 
broadly speaking, the study outlines the rationale for a 
“multi-orthogonal” approach integrating conventional 
chemotherapy with inhibitors directed against different 
forms of oncogenes and oncogenic stress (Figure 5F). 
Importantly, the “multi-orthogonal” approach needs to be 
tailored to the molecular physiology of the target cancer. 
With an ever-expanding catalogue of the mutational 
landscape of glioblastomas, dedication to understanding 
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the molecular physiologies associated with these 
landscapes will be essential for multi-orthogonal based 
therapeutic approaches. Based on the present study, it 
is our belief that optimal oncologic strategies against 
cancers with highly pliable molecular circuit will require 
meaningful integration of orthogonally acting, targeted 
agents and non-selective chemotherapeutic agent tailored 
to the genetic landscape of the tumor. 
MAterIAls And MetHods
cell lines and reagents
The U87MG parental, U87MG EGFRvIII, U178MG 
tet-EGFRvIII cell lines, and transformed mouse Ink4a/
Arf(-/-) astrocytes, Ink4a/Arf(-/-) EGFRvIII cells, Ink4a/
Arf(-/-) EGFRvIII Gefitinib/Erlotinib resistant cells, 
and Ink4a/Arf(-/-) PDGF-β cells have been previously 
described [29, 31, 42]. U87MG parental H2B-GFP and 
U87MG EGFRvIII H2B-GFP cells were constructed by 
infecting U87MG parental and U87MG EGFRvIII cells 
with a H2B-GFP construct [43] generously provided by 
Dr. David Pellman (Dana Farber Cancer Institute, Boston). 
TMZ (AK Scientific, Mountain View, CA) and BI2536 
(ChemieTek, Indianapolis, IN) were dissolved in DMSO 
(Sigma Aldrich, St. Louis, MO). Doxycycline (Clontech, 
Mountain View, CA) was dissolved in deionized 
water. Cells were cultured in DMEM medium (Gibco) 
supplemented with 10% fetal bovine serum (FBS, Gibco), 
1% Pen-Strep (Gibco) and 1% GlutaMax (Gibco) unless 
otherwise specified. Tetracycline free serum (Clontech, 
Mountain View, CA) was used for experiments involving 
doxycycline. 
sirnA library screen
The initial siRNA screen was performed with the 
DNA damage response subset v2.0 library (Qiagen, 
Valencia, CA) as previously described [11]. Each gene 
target is represented by two distinct siRNAs as previously 
described [44]. In brief, The QIAGEN siRNA library 
was grided into 96 well plates. Each plate also contained 
2 GFP-targeted siRNAs, 2 LacZ-targeted siRNAs at 20 
nM. For each plate, there were 16 wells containing no 
siRNA as controls. U87 or U87-EGFRvIII cells were 
seeded in 96-well plates (BD Biosciences) at 1,000 cells 
per well in 80 ul of medium. Twenty-four hours later, a 
transfection mix of 15.5 ml of OptiMEM (Invitrogen), 0.5 
ml of HiPerFect (QIAGEN), and 4 ml of 2 mM siRNA 
oligonucleotide was added to each well. Viability at 96 
hours was measured using the CellTiter-Glo Luminescent 
Cell Viability Assay kit (Promega). The experiment was 
performed twice to allow statistical analysis of the targets. 
The corrected viability for each siRNA oligonucleotide 
was calculated as a percentage of the mean viability of 
the 16 control wells on each plate. The corrected viability 
of the U87MG-EGFRvIII cell line was divided by the 
corrected viability of the U87MG cell line to calculate 
the relative viability for each respective gene target. The 
mean viability of the U87MG-EGFRvIII relative to the 
U87MG cell line for each gene target, along with the 
SEM, was calculated from 4 individual corrected viability 
values that represent duplicate results from the 2 different 
oligonucleotides on each plate targeting a particular gene. 
The siRNA targets are then ranked based on this index 
[28].
live cell imaging
U87MG H2B-GFP and U87MG EGFRvIII H2B-
GFP cells were grown on 12-well glass-bottom dishes 
(MatTek, Ashland, MA) overnight (5×104 cells per well). 
Images were acquired automatically from each well using 
a Nikon TE2000E PFS inverted microscope fitted with a 
20×Nikon Plan Fluor objective (Nikon, Melville, NY), a 
linearly encoded stage (Prior ProScan, Prior Scientific, 
Rockland, MA) and a Hamamatsu Orca-ER CCD camera 
(Hamamatsu, Bridgewater, NJ). The microscope was 
controlled using NIS Element (Nikon). The microscope 
was housed in a custom-designed 37°C chamber with a 
secondary internal chamber that delivered humidified 5% 
CO2. Fluorescence and differential interference contrast 
images were obtained every 15 min for a period of 72 h. 
For experiments involving TMZ, the cells were treated 
with 100 µM TMZ for 24 h prior to imaging.
I-sceI recombination assay
DR-GFP assays were performed using U87MG 
DR-GFP and U2OS DR-GFP subclones as previously 
described [27]. Briefly, plasmids phprtDRGFP and 
pCBASce were generously provided by Dr. David 
Weinstock (Dana Farber Cancer Institute, Boston). 
U87MG and U2OS were transfected with phprtDRGFP 
via FuGENE HD (Roche, Indianapolis, IN). Subclones 
harboring single stable integration identified by Southern 
blotting were generously provided by Dr. David Kozono 
(Dana Farber Cancer Institute, Boston). 24 h after 
pCBASce transfection to induce DSB at I-SceI site of 
the integrated phprtDRGFP construct, cells were treated 
with either BI2536 (25 nM) or control for an additional 
24 h, then trypsinized and subjected to FACS analysis to 
identify the proportion of GFP-expressing cells.
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subcutaneous xenograft and GeMM-derived 
glioblastoma models
All animal studies were performed in accordance 
with the Animal Care and Use Rules at the University of 
California San Diego under protocol S13070. 1×106 cells 
of exponentially expanding U87MG, U87MG EGFRvIII, 
murine Ink4a/Arf(-/-) EGFRvIII, its gefitinib resistant 
line GR-7, or murine Ink4a/Arf(-/-) PDGF-β, in 100 µL 
of PBS were injected into the right flank of 4-5weeks old 
athymic nude mice. Tumors were measured with a vernier 
caliper, and tumor volumes(TVs) were calculated using 
width (a) and length (b) measurements (TV = a2×b/2, 
where a≤b). Relative tumor volume (RTV) was calculated 
by (RTV = TVt/TV0, where TV0 is the tumor volume 
measured when starting drug treatment). The anti-tumor 
effect of drug treatment was calculated by drug treated/
control (T/C) ratio (T/C = RTVtreated÷RTVcontrol×100%). 
Mice were euthanized when tumor volume reached 
2000 mm3 or tumors became ulcerated in accordance 
with our institutional guidelines for animal welfare and 
experimental conduct.
Intracranial brain tumor allograft models
105 cells of the exponentially expanding murine 
Ink4a/Arf(-/-) EGFRvIII or G12 cells were injected 
into 4-5weeks old athymic nude mice using a mouse 
stereotaxic instrument (Stoelting Co, Wood Dale, IL) 
according to the protocol previously described [45]. 
Survival was recorded until the onset of neurologic 
sequelae or cachexia. Mice were euthanized in accordance 
with our institutional guidelines for animal welfare and 
experimental conduct. The survival curve was calculated 
by GraphPad Prism 5 (GraphPad, La Jolla, CA) using the 
method of Kaplan-Meier. p values were analyzed using the 
logrank (Mantel-Cox) test.
TMZ was given at 15 mg/kg by oral gavage once 
per day for three days at indicated time point after 
implantation. BI2536 was given consecutively at 25 mg/kg 
by i.v.injection twice per week for four weeks beginning 
at indicated time point. Gefitinib was administered via 
oral gavage at 200 mg/kg weight once per day, 5 days per 
week for four weeks. For all experiments, 5-6 mice were 
randomized to each treatment group. 
Validation of screen results using clonogenic 
assays
Confirmation of PLK1 results was performed using 
two additional siRNAs directed targeting PLK1 that were 
distinct from the siRNAs included in the library (Hs_
PLK1_6 FlexiTube siRNA and Hs_PLK1_7 FlexiTube 
siRNA, Qiagen). 20 nM of siRNA was transfected 
using RNAiMax (Invitrogen, Carlsbad, CA) according 
to manufacturer’s protocol for 48 h prior to subsequent 
Western blotting and clonogenic assay. Cells were re-
plated in serial dilution for clonogenic survival assessment 
in triplicates and repeated at least twice as previously 
described [11]. 
cell synchronization by double thymidine 
blocking (dtb)
Briefly, the seeded cells were washed with 
phosphate-buffered saline (PBS, Invitrogen) then 
incubated with 2 mM thymidine (Sigma) for 16 h. Fresh 
complete DMEM media was incubated for 8 h to release 
cells. Then the cells were subjected to a second thymidine 
block by thymidine for another 16 h. The cells were 
released to fresh DMEM media. Cell cycle profiling was 
analyzed using FACS Calibur system (BD Biosciences, 
San Jose, CA) as previously described [46].
Western blot
Lysates were prepared using a RIPA lysis buffer 
(Sigma) supplemented with a cocktail of protease 
inhibitors (Roche, Indianapolis, IN), incubated for 15 
min on ice, and then clarified by centrifugation. Equal 
amounts of protein were resolved by SDS-polyacrylamide 
gel electrophoresis and electro-transferred to nitrocellulose 
membranes (Invitrogen, Carlsbad, CA). Membranes were 
blocked for 1 h in 5% fat-free milk dissolved in TBS 
containing 0.1% Tween-20 and incubated overnight at 
4°C with indicated antibodies, including anti-EGFR 
(Cell Signaling Tech [CST], Danvers, MA), anti-pT210 
PLK1 (CST), anti-pSer10 Histone H3 (labeled as pH3, a 
marker of cells in mitosis (CST), anti-γH2AX (a marker 
for DNA damage, Millipore, Billerica, MA) and anti-
pS14 Rad51 (kindly provided by Dr. Fumiko Esashi, 
University of Oxford, UK), diluted in the same blocking 
buffer. For loading control, membranes were probed with 
anti-β-actin (Sigma) or anti-Ku86 (Santa Cruz Biotech, 
Dallas, TX). After washing, membranes were incubated 
with appropriate secondary (Pierce, Rockford, IL) 
antibodies conjugated to horseradish peroxidase. For total 
protein level of PLK1 and Rad51, the p-antibody probed 
membranes were stripped and re-probed with anti-PLK1 
(Santa Cruz Biotech) or anti-Rad51 (Santa Cruz Biotech) 
antibodies, respectively. Blots were developed with 
SuperSignal Chemiluminescence reagent (Pierce) and 
scanned with Perfection V700 photo scanner (Epson). The 
band density was analyzed by AlphaView (ProteinSimple). 
Phosphorylation level of Rad51 and PLK1 was compared 
with its total protein level, respectively, after normalized 
with loading control individually.
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comet assay
The comet assay (Trevigen, Gaithersburg, MD) 
was performed according to manufacturer’s protocol 
using neutral conditions. After lysis, the slides were 
washed twice with 1× Tris-borate EDTA buffer solution, 
pH 8.3 (TBE) for 10 min. The slides were placed in a 
horizontal electrophoresis chamber and covered with 
TBE buffer. Electrophoresis was carried out at the rate of 
1.0 V/cm for 20 min. The slides were removed from the 
electrophoresis chamber, washed in deionized water for 
5 min and immersed in ice cold 100% ethanol for 5 min. 
Subsequently, the slides were air dried, DNA was stained 
with 50 μl of SYBR Green I dye (Trevigen, 1:10,000 in 
Tris-EDTA buffer, pH 7.5) for 20 min in the refrigerator 
and immediately analyzed using upright fluorescence 
microscope (Nikon, Melville, NY), and data was analyzed 
using CometScore (TriTek, Sumerduck, VA).
Immunofluorescence staining
After drug treatment, cells were trypsinized, washed 
once with PBS, centrifuged at 500 rpm for 5 min using 
a cytospin (Thermo Fisher Scientific, Waltham, MA) and 
seeded onto poly-l-lysine (PLL)-coated coverslips. The 
cells were then fixed with 4% para-formaldehyde for 20 
min, blocked in 2% BSA/PBS for 30 min, and incubated 
in primary anti-pH3 and anti-γH2AX antibody overnight 
(4°C). Cells were then washed three times in 2% BSA/
PBS, incubated in Alexa Fluor 488 and Alexa Fluor 594 
secondary antibodies for 1 hour at room temperature. 
DAPI was added to stain nuclei. Cells were imaged on 
an upright fluorescence microscope (Nikon, Melville, 
NY), and the data was analyzed using FociCounter (Anna 
Jucha, University of Wrocław, Poland). Cells were scored 
based on whether they harbor ≥10 γH2AX foci.
For multipolar and monopolar mitotic spindles 
staining, cells were washed with PBS and fixed with cold 
methanol for 20 min at -20°C, followed by incubation 
with primary antibodiesmin including Cep192 (SPD-
2, A. Dammermann, K. Oegema Lab) and α-tubulin 
(DM1α, Sigma). Images were recorded on a Deltavision 
microscope at 1 × 1 binning with a 100× NA 1.3 
U-planApo objective. Z-stacks (0.2 µm sections) were 
deconvolved using softWorRx (Applied Precision) and 
maximum intensity projections were imported into Adobe 
Photoshop CS4 (Adobe) for analysis.
Flow cytometry
After fixation, cells were permeablized by PBS 
containing 0.25% Triton X-100 for 15 min followed by 
incubation with primary antibodies against pH3 (CST), 
and γH2AX (Millipore) for 1h. After wash once with PBS 
containing 1% BSA, cells were incubated with Alexa Fluor 
488-conjugated goat anti-rabbit IgG (H+L) and Alexa 
Fluor 647-conjugated goat anti-mouse IgG1 antibodies 
(Invitrogen) for 30 min. The cells were then treated with 
propidium iodide (PI)/ RNase A staining buffer for another 
30 min. Fluorescence-activated cell sorting (FACS) was 
performed with FACS Calibur (BD Biosciences, San Jose, 
CA). For negative control, the samples were incubated 
with secondary antibodies (without incubation with the 
primary antibodies) and PI/RNase A staining buffer. 3×104 
cells were analyzed for each sample. Data was analyzed 
with FlowJo software (BD Bioscience).
cell viability assays
Cells were seeded in a 96-well plate at a density of 
1×103 cells per well. 12-15 h later, drugs or control were 
added to achieve indicated concentration in quadruplicate 
wells and incubated for 72 h. Viability was assessed with 
the WST-1 cell proliferation reagent according to the 
manufacturer’s instructions (Clontech, Mountain View, 
CA). Drug treatments were normalized to the control cells 
for each cell line to calculate percent cell viability. 
Clonogenic survival assays were performed as 
previously described [11].
Analysis the tcGA and reMbrAndt 
glioblastoma datasets
The EGFRvIII status of the TCGA glioblastoma 
samples were provided by Dr. Cameron Brennan 
(Memorial Sloan Kettering Cancer Center, New York). 
TCGA mRNA expression data acquired via Affymetrix HT 
Human Genome U133 array were downloaded as Level 
3 gene collapsed data (https://tcga-data.nci.nih.gov/tcga/). 
PLK1 mRNA expression data was normalized to cyclin A 
and B enrichment scores (ES) using single sample Gene 
Set Enrichment Analysis (ssGSEA) employing previously 
published methods [47] and compared by EGFR or 
PDGF-β status. A box and whiskers plot was employed. p 
values were obtained by boot strapping the individual test 
statistics from two sided t-tests against the test statistics 
from 1500 simulations using random gene lists. 
Genomic expression sets and clinical data were 
acquired from the TCGA Data Portal (May 2013) https://
tcga-data.nci.nih.gov/tcga/ and the REMBRANDT https://
caintegrator.nci.nih.gov/rembrandt/. A published DNA 
damage accumulation mRNA signature that was induced 
by IR in glioblastoma cells was identified [33], then 
correlated the signature to PLK1 expression. Values of 
probes designed to assess the same gene were averaged. 
Expression sets were generated using the Bioconductor 
package http://www.bioconductor.org/ using the statistics 
software R http://www.r-project.org/ (Mountain View, 
CA).
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statistical analysis
In general, data were presented as the means 
with their respective standard errors (SEM) or standard 
deviation (SD). Significance was tested by unpaired two-
tailed Student t test using Office Excel 2007 (MicroSoft, 
Santa Clara, CA) unless otherwise indicated. p values < 
0.05 were considered statistically significant. Details for 
additional methods, including double thymidine blocking 
(DTB) synchronization, flow cytometry, Western blotting, 
Comet assay, Immunofluorescence staining, Clinical 
analysis, Cell viability assay, are described in SI text.
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